Nano Cures Inc., an Austin, Texas-based clinical stage biotechnology and infectious disease immunity platform company, raised $90M pre-IPO funding round.
The investment will be led by a $20M commitment from Opulence Capital Management, a Dubai based private investment fund, with existing and new investors participating.
The company intends to use the funds to accelerate the global scale up of its Cures Platform for Covid-19 variants, including vaccines and persistent immunity delivery.
Led by Steve Papermaster, Chief Executive Officer, Nano has developed novel self-administered technology that moves delivery beyond syringes and shots, to an array of nasal, dermal, ophthalmic, sub-lingual, and oral options. Nano will open up its Cures Platform to other pharmaceutical companies and their vaccines, providing new ways to conquer deliver billions of doses directly to those in need.
The company is accelerating plans to bring its Cures Platform for Covid-19 (and variants) to emerging regions such as GCC, Southeast Asia, Latin America and Central/Southern Europe.
Furthermore, Nano is developing universal pan coronavirus vaccines and therapeutics for annual protection against known and emerging coronaviruses, which will be critical to avoiding future global and regional public health and economic threats.
